BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World J Clin Oncol 2015; 6(6): 252-263 [PMID: 26677438 DOI: 10.5306/wjco.v6.i6.252]
URL: https://www.wjgnet.com/2218-4333/full/v6/i6/252.htm
(421) (365) (0) (0) (17) (21267) (128)
Number Citing Articles
1
Yanwu Zhang, Yidong Lv, Yaodong Niu, Hongge Su, Aiqiang Feng. Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China. Medical Science Monitor 2017; 23 doi: 10.12659/MSM.902637
2
Fariba Binesh, Elahah Jafaripour, Nasim Namiranian, Hasan Ali Vahedian, Fatemeh Pourhosseini, Maryam Vajihinejad. Association of CK5/6 Expression with Five-Year Mortality Rate in Triple-Negative Breast Cancer. International Journal of Cancer Management 2026; 19(1) doi: 10.5812/ijcm-172033
3
Soo-Yeon Hwang, Seojeong Park, Youngjoo Kwon. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacology & Therapeutics 2019; 199 doi: 10.1016/j.pharmthera.2019.02.006
4
Cláudia Lopes, Paulina Piairo, Alexandre Chícharo, Sara Abalde-Cela, Liliana R. Pires, Patrícia Corredeira, Patrícia Alves, Laura Muinelo-Romay, Luís Costa, Lorena Diéguez. HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device. Cancers 2021; 13(17) doi: 10.3390/cancers13174446
5
Bowen Li, Jianwu Tian, Xin Xie, Fu Zhang, Chongzhi Wu, Yi Shan, Guobin Qi, Wentao Song, Yuan Ping, Bin Liu. Overcoming ROS Resistance of Photodynamic Therapy with Self‐Assembled Nano‐Prodrugs for Efficient Triple‐Negative Breast Cancer. Advanced Functional Materials 2024; 34(4) doi: 10.1002/adfm.202309524
6
. 2018;  doi: 10.70675/85185e48z640cz4823z8ea3z8f24dc88fcdd
7
Mansi Shah, Ryan Cardenas, Belinda Wang, Jenny Persson, Nigel P. Mongan, Anna Grabowska, Cinzia Allegrucci. HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells. Molecular Cancer 2017; 16(1) doi: 10.1186/s12943-017-0605-z
8
Shahensha Shaik, Ha’reanna Campbell, Christopher Williams. NURR1 Is Differentially Expressed in Breast Cancer According to Patient Racial Identity and Tumor Subtype. BioMedInformatics 2022; 2(4) doi: 10.3390/biomedinformatics2040045
9
Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad. Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis. PLOS ONE 2019; 14(6) doi: 10.1371/journal.pone.0218030
10
Ruihao Li, Xiaochun Hu, Fangjian Shang, Wenjing Wu, Haijun Zhang, Yixuan Wang, Jiawei Pan, Shuo Shi, Chunyan Dong. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals. Acta Biomaterialia 2022; 148 doi: 10.1016/j.actbio.2022.06.011
11
Yu Zhou, Yingqi Che, Zhongze Fu, Henan Zhang, Huiyu Wu. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. Frontiers in Public Health 2022; 10 doi: 10.3389/fpubh.2022.902378
12
Jessica Iorio, Icro Meattini, Simonetta Bianchi, Marco Bernini, Virginia Maragna, Luca Dominici, Donato Casella, Vania Vezzosi, Lorenzo Orzalesi, Jacopo Nori, Lorenzo Livi, Annarosa Arcangeli, Elena Lastraioli. hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0592-1
13
Chun-Yu Liu, Tzu-Ting Huang, Pei-Yi Chu, Chun-Teng Huang, Chia-Han Lee, Wan-Lun Wang, Ka-Yi Lau, Wen-Chun Tsai, Tzu-I Chao, Jung-Chen Su, Ming-Huang Chen, Chung-Wai Shiau, Ling-Ming Tseng, Kuen-Feng Chen. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. Experimental & Molecular Medicine 2017; 49(8) doi: 10.1038/emm.2017.114
14
. 2022;  doi: 10.70675/13ab50cfz7edbz4a44z918aza657b9614a4d
15
Nur Amalina Noralidin, Muhammad Luqman Nordin, Rumaizi Shaari, Kamarul Ariffin Hambali, Mohd Farhan Hanif Reduan, Abu Hassan Nordin, Nurshahirah Shaharulnizim, Mimi Armiladiana Mohamad, Ahmad Khusairi Azemi. Bitter Bean (Parkia speciosa) Aqueous Extract: A Potential Natural Compound Agent Against Mammary Carcinoma in BALB/c Mice. Revista Brasileira de Farmacognosia 2026; 36(1) doi: 10.1007/s43450-025-00715-y
16
Teng Pan, Tingting Mao, Haiyan Yang, Haiyu Wang, Yadong Wang. Silencing of TGIF sensitizes MDA‑MB‑231 human breast cancer cells to cisplatin‑induced apoptosis. Experimental and Therapeutic Medicine 2018;  doi: 10.3892/etm.2018.5780
17
Kamali Chakkaravarthi, Rajashree Ramesh, Thirunavukkarasu Palaniyandi, Gomathy Baskar, Sandhiya Viswanathan, Mugip Rahaman Abdul Wahab, Hemapreethi Surendran, Maddaly Ravi, Asha Sivaji. Prospectives of mirna gene signaling pathway in triple-negative breast cancer. Pathology - Research and Practice 2023; 248 doi: 10.1016/j.prp.2023.154658
18
Junping Liu, Wei Zhang, Wanxia Cai, Yumei Chen, Xiaozhong Cai, Donge Tang, Min Tang, Yong Dai. Multi-Omics Analyses Revealed GOLT1B as a Potential Prognostic Gene in Breast Cancer Probably Regulating the Immune Microenvironment. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.805273
19
Humaira Khan, Muhammad Raza Shah, Jiri Barek, Muhammad Imran Malik. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry 2023; 158 doi: 10.1016/j.trac.2022.116813
20
Elisa Roda, Fabrizio De Luca, Carlo Alessandro Locatelli, Daniela Ratto, Carmine Di Iorio, Elena Savino, Maria Grazia Bottone, Paola Rossi. From a Medicinal Mushroom Blend a Direct Anticancer Effect on Triple-Negative Breast Cancer: A Preclinical Study on Lung Metastases. Molecules 2020; 25(22) doi: 10.3390/molecules25225400
21
Marissa Howard, James Erickson, Zachary Cuba, Shawn Kim, Weidong Zhou, Purva Gade, Rachel Carter, Kelsey Mitchell, Heather Branscome, Daivik Siddhi, Fatimah Alanazi, Yuriy Kim, Robyn P. Araujo, Amanda Haymond, Alessandra Luchini, Fatah Kashanchi, Lance A. Liotta. A secretory form of Parkin‐independent mitophagy contributes to the repertoire of extracellular vesicles released into the tumour interstitial fluid in vivo. Journal of Extracellular Vesicles 2022; 11(7) doi: 10.1002/jev2.12244
22
Teresa Maria Martorana, Gabriele Ricciardi, Pietro Tralongo, Vincenzo Fiorentino, Cristina Pizzimenti, Mariausilia Franchina, Maria Adele Marino, Mariacarmela Santarpia, Giovanni Tuccari, Antonio Ieni, Guido Fadda, Maurizio Martini, Valeria Zuccalà. Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities. Pathology - Research and Practice 2025; 275 doi: 10.1016/j.prp.2025.156226
23
Guangcun Cheng, Xuemei Fan, Mingang Hao, Jinglong Wang, Xiaoming Zhou, Xueqing Sun. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Molecular Cancer 2016; 15(1) doi: 10.1186/s12943-016-0515-5
24
Emmanuel Ifeanyi Obeagu. Hypoxia-inducible factors in breast cancer: prognostic indicators and emerging biomarkers: narrative review. Annals of Medicine & Surgery 2025; 87(9) doi: 10.1097/MS9.0000000000003500
25
Yuxin Xie, Qiheng Gou, Qianqian Wang, Xiaorong Zhong, Hong Zheng. The role of BRCA status on prognosis in patients with triple-negative breast cancer. Oncotarget 2017; 8(50) doi: 10.18632/oncotarget.19895
26
Rui Hong, Hongyu Sun, Dujuan Li, Weihuang Yang, Kai Fan, Chaoran Liu, Linxi Dong, Gaofeng Wang. A Review of Biosensors for Detecting Tumor Markers in Breast Cancer. Life 2022; 12(3) doi: 10.3390/life12030342
27
Nilofer Shaikh, Sanket Bapat, Muthukumarasamy Karthikeyan, Renu Vyas. A Review on Computational Analysis of Big Data in Breast Cancer for Predicting Potential Biomarkers. Current Topics in Medicinal Chemistry 2022; 22(21) doi: 10.2174/1568026622666220907121942
28
Eliana Noelia Alonso, María Julia Ferronato, María Eugenia Fermento, Norberto Ariel Gandini, Alejandro López Romero, Josefina Alejandra Guevara, María Marta Facchinetti, Alejandro Carlos Curino. Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells. Oncotarget 2018; 9(34) doi: 10.18632/oncotarget.25174
29
Abhishek Kanugo, Rupesh K. Gautam, Mohammad Amjad Kamal. Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple- Negative Breast Cancer (TNBC). Current Pharmaceutical Biotechnology 2022; 23(13) doi: 10.2174/1389201023666211230113658
30
Charu Kothari, Mazid Abiodoun Osseni, Lynda Agbo, Geneviève Ouellette, Maxime Déraspe, François Laviolette, Jacques Corbeil, Jean-Philippe Lambert, Caroline Diorio, Francine Durocher. Machine learning analysis identifies genes differentiating triple negative breast cancers. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-67525-1
31
Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, Gaurisha Alias Resha Ramnath Naik, Sarika Yadav, Shreya Srivastava, Amrita Arup Roy, Sudheer Moorkoth, Srinivas Mutalik, Namdev Dhas. Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer. Journal of Drug Delivery Science and Technology 2024; 93 doi: 10.1016/j.jddst.2024.105401
32
Heejin Jun, Junsu Kim, Soomin Eom, Diane Jeong, Sebyung Kang. Targeted Therapy for CD13‐Overexpressing Triple‐Negative Breast Cancers Using Apoptosis‐Inducing Protein Cage Nanoparticles. Macromolecular Bioscience 2026; 26(2) doi: 10.1002/mabi.202500645
33
Nihad Al-Othman, Mamoun Ahram, Moath Alqaraleh. Role of androgen and microRNA in triple-negative breast cancer. Breast Disease 2020; 39(1) doi: 10.3233/BD-190416
34
Bayan Zoatier, Metin Yildirim, Mehmet Abdullah Alagoz, Derya Yetkin, Burcin Turkmenoglu, Serdar Burmaoglu, Oztekin Algul. N-(benzazol-2-yl)-2-substituted phenylacetamide derivatives: Design, synthesis and biological evaluation against MCF7 breast cancer cell line. Journal of Molecular Structure 2023; 1285 doi: 10.1016/j.molstruc.2023.135513
35
Michaela Aubele, Manfred Schmitt, Rudolf Napieralski, Stefan Paepke, Johannes Ettl, Magdalena Absmaier, Viktor Magdolen, John Martens, John A. Foekens, Olaf G. Wilhelm, Marion Kiechle. The Predictive Value ofPITX2DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Disease Markers 2017; 2017 doi: 10.1155/2017/4934608
36
Kazem Mashayekhi, Maryam Rahnama, Md Saidur Rahman, Anisha Prasad, Shahidul M. Islam. Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers. Molecular Therapy Oncology 2026; 34(1) doi: 10.1016/j.omton.2026.201138
37
Akihiro Sakai, Yuki Miyai, Yukihiro Shiraki, Ryota Ando, Nobutoshi Esaki, Tadashi Iida, Takahiro Sugie, Masahiro Shibata, Toyone Kikumori, Norikazu Masuda, Hiroyoshi Y. Tanaka, Mitsunobu R. Kano, Atsushi Enomoto, Shinji Mii. Increased Meflin Expression in Cancer-Associated Fibroblasts Restrains Tumor Cell Proliferation and Shapes Vessel-Rich Stroma in Triple-Negative Breast Cancer. The American Journal of Pathology 2026; 196(5) doi: 10.1016/j.ajpath.2026.01.006
38
Miseon Lee, In Ah Park, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee. Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Journal of Pathology and Translational Medicine 2019; 53(3) doi: 10.4132/jptm.2019.02.08
39
. 2016;  doi: 10.70675/257690c1z05c6z40e3z8244ze9ab503d345a
40
Xiaolu Yang, Tiantian Tang, Tao Zhou. Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis. World Journal of Surgical Oncology 2023; 21(1) doi: 10.1186/s12957-023-03261-w
41
Xuan-Yu Mao, Jesus Perez-Losada, Mar Abad, Marta Rodríguez-González, Cesar A Rodríguez, Jian-Hua Mao, Hang Chang. iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers. World Journal of Clinical Oncology 2022; 13(7): 616-629 doi: 10.5306/wjco.v13.i7.616
42
Bihui Li, Shuangxi Li, Ruihan Li, Menzhen Li, Zhaoquan Huang. Single cell sequencing and computational findings reveal anti-estrogen receptor-positive breast cancer roles of formononetin. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-06133-3
43
Serdar Karakurt, Irem Mukaddes Bilgiseven, Kemal Bas, Cigdem Gokcek Sarac. MicroRNAs: Role in Cancer Progression, Diagnostics and Therapy. Advances in Biochemistry in Health and Disease 2026; 34 doi: 10.1007/978-3-032-08824-6_9
44
. 2023;  doi: 10.70675/d9479ad5z9c48z482bz84a9z332d80c8b3e8
45
Halima Alsamri, Hussain El Hasasna, Yusra Al Dhaheri, Ali H. Eid, Samir Attoub, Rabah Iratni. Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00743
46
Ivan Dědek, Vítězslav Hrubý, Petr Jakubec, Klára Gajdošová, Kateřina Poláková, Jana Dzíbelová, Michal Otyepka. High-sensitivity EPCR detection using a G-Arg nanointerface: A new electrochemical platform targeting TNBC biomarkers. Sensing and Bio-Sensing Research 2026; 52 doi: 10.1016/j.sbsr.2026.101017
47
Ishita Gupta, Balsam Rizeq, Semir Vranic, Ala-Eddin Al Moustafa, Halema Al Farsi. Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets. International Journal of Molecular Sciences 2020; 21(18) doi: 10.3390/ijms21186750
48
Dana M. Zaher, Iman M. Talaat, Amal Hussein, Mahmood Y. Hachim, Hany A. Omar. Differential expression of pyruvate dehydrogenase E1A and its inactive phosphorylated form among breast cancer subtypes. Life Sciences 2021; 284 doi: 10.1016/j.lfs.2021.119885
49
Binbin Tan, Ying Zhang, Tiantian Zhang, Jinsong He, Xueying Luo, Xiqing Bian, Jianlin Wu, Chang Zou, Yangzhi Wang, Li Fu. Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC–MS platform. Biomedical Chromatography 2020; 34(10) doi: 10.1002/bmc.4922
50
Shuai Yuan, Jiangxia Li, Weimei Liu, Meitian Ren, Lianyu Lin, Shuangying Hao, Lina Yang. CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-15205-6
51
Deepshikha Rathore, Ishita Agarwal, Smit Patel, Nishita Adnani, Nandani Dharwal, Nirali Shukla, Heena V. Dave. Molecular interplay of lncRNAs, miRNAs, and mRNAs axes in triple-negative breast cancer: implications for metastatic progression. Journal of Applied Genetics 2026; 67(3) doi: 10.1007/s13353-026-01061-y
52
Silvia Cecilia Pacheco-Velázquez, Juan Carlos Gallardo-Pérez, Daniel Díaz, Alhelí Adán-Ladrón de Guevara, Diana Xochiquetzal Robledo-Cadena, Emma Saavedra, Luz Ruiz-Godoy, Luis Roberto Jimenez-Hernández, Jesús Vargas-Barrón, José Luis Aguilar-Ponce, Sara Rodríguez-Enríquez. Heart myxoma develops oncogenic and metastatic phenotype. Journal of Cancer Research and Clinical Oncology 2019; 145(5) doi: 10.1007/s00432-019-02897-0
53
Elnaz Faghfuri, Mohsen Sagha, Amir Hossein Faghfouri. The Cytotoxicity Effect of Curcumin Loaded Folic Acid Conjugated-Nanoparticles on Breast Cancer Cells and Its Association with Inhibition of STAT3 Phosphorylation. Journal of Cluster Science 2022; 33(5) doi: 10.1007/s10876-021-02125-1
54
Deepshikha Rathore, Sweny Jain, Nandani Dharwal, Nirali Shukla, Shanaya Patel, Heena Dave. Biomarker Landscape in Cancer Research. 2025;  doi: 10.1016/B978-0-443-33902-8.00014-6
55
Felipe C. M. Zoppino, Martin E. Guerrero-Gimenez, Gisela N. Castro, Daniel R. Ciocca. Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4621-1
56
Brianna J. McIntosh, Griffin G. Hartmann, Sean A. Yamada‐Hunter, Phillip Liu, Camille F. Williams, Julien Sage, Jennifer R. Cochran. An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma. Bioengineering & Translational Medicine 2023; 8(6) doi: 10.1002/btm2.10573
57
Fouzia Guestini, Katsuhiko Ono, Minoru Miyashita, Takanori Ishida, Noriaki Ohuchi, Saki Nakagawa, Hisashi Hirakawa, Kentaro Tamaki, Yasuyo Ohi, Yoshiaki Rai, Yasuaki Sagara, Hironobu Sasano, Keely May McNamara. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 2019; 173(2) doi: 10.1007/s10549-018-4985-6
58
Sohit Kashyap, Vishal Patidar, Anil Kumar, Prachi Sahu, Monisha Dhiman, Pardeep Garg, Aklank Jain, Anjana Munshi. Proteomic signatures in triple-negative breast cancer. Journal of Proteomics 2026; 325 doi: 10.1016/j.jprot.2026.105598
59
Aysha Alneyadi, Zohra Nausheen Nizami, Hanan E. Aburawi, Soleiman Hisaindee, Muhammad Nawaz, Samir Attoub, Gaber Ramadan, Nehla Benhalilou, Mazoun Al Azzani, Yassine Elmahi, Aysha Almeqbali, Khalid Muhammed, Ali H. Eid, Ranjit Vijayan, Rabah Iratni. Synthesis of New Chromene Derivatives Targeting Triple-Negative Breast Cancer Cells. Cancers 2023; 15(10) doi: 10.3390/cancers15102682
60
Zhen Li, Jian Dong, Tianning Zou, Chengzhi Du, Siyuan Li, Ceshi Chen, Rong Liu, Kunhua Wang. Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triple-negative breast cancer. Oncotarget 2017; 8(7) doi: 10.18632/oncotarget.14135
61
Shreyasi Kundu, P.K. Suresh. Triple Negative Breast Cancer Heterogeneity and Tumour Microenvironment-based Model Systems’ Focus on Druggable Targets. Current Molecular Medicine 2025; 25(12) doi: 10.2174/0115665240387430250508080548
62
Alexus Acton, William J. Placzek. Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer. Cancers 2023; 15(18) doi: 10.3390/cancers15184481
63
Richard D. A. Wilkinson, Roberta E. Burden, Sara H. McDowell, Darragh G. McArt, Stephen McQuaid, Victoria Bingham, Rich Williams, Órla T. Cox, Rosemary O’Connor, Nuala McCabe, Richard D. Kennedy, Niamh E. Buckley, Christopher J. Scott. A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer. Journal of Oncology 2019; 2019 doi: 10.1155/2019/3980273
64
Leila Kudreyeva, Fatima Kanysh, Aliya Sarsenbayeva, Moldir Abu, Duisek Kamysbayev, Kamilya Kedelbayeva. HER-2-Targeted Electrochemical Sensors for Breast Cancer Diagnosis: Basic Principles, Recent Advancements, and Challenges. Biosensors 2025; 15(4) doi: 10.3390/bios15040210
65
Diya Agarwal, Ammana Sathwika Reddy, Balasani Ashwitha, Muppasani Thanvitha, Mamidala Ravalika. Triple-negative breast cancer: unmet needs and emerging targeted and immunotherapeutic approaches. International Journal of Basic & Clinical Pharmacology 2026; 15(5) doi: 10.18203/2319-2003.ijbcp20262883
66
Ramya Ambur Sankaranarayanan, Alexandru Florea, Susanne Allekotte, Andreas T. J. Vogg, Jochen Maurer, Laura Schäfer, Carsten Bolm, Steven Terhorst, Arno Classen, Matthias Bauwens, Agnieszka Morgenroth, Felix M. Mottaghy. PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer. EJNMMI Research 2022; 12(1) doi: 10.1186/s13550-022-00932-9
67
R. M. Paltuev. Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. Tumors of female reproductive system 2019; 15(4) doi: 10.17650/1994-4098-2019-15-4-30-49
68
Ravinder Verma, Yashmi Jain, Laxmi Rani, Deepak Kaushik, Shailendra Bhatt, Pooja Mathur. Exploring the Potential of Nanomolecular Therapeutic Options and Novel Biomarkers in Triple-negative Breast Cancer Treatment. Current Cancer Therapy Reviews 2025; 21(5) doi: 10.2174/0115733947297237240530055719
69
Eman F. Abdelhaleem, Mohammed K. Abdelhameid, Asmaa E. Kassab, Manal M. Kandeel. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. European Journal of Medicinal Chemistry 2018; 143 doi: 10.1016/j.ejmech.2017.10.075
70
Hamsa D, Praveen Kumar K, Shanmughavel P, Poornima A, Sumathi S. Screening of key modulatory genes by Degalactotigonin in Triple Negative Breast Cancer cells – An in silico approach. Meta Gene 2020; 26 doi: 10.1016/j.mgene.2020.100799
71
Elizabeth A. Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford, Jesika S. Faridi. Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 2021; 20(4) doi: 10.1158/1535-7163.MCT-20-0373
72
Shuang Hao, Zhi-Xian He, Ke-Da Yu, Wen-Tao Yang, Zhi-Min Shao. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. Oncotarget 2016; 7(17) doi: 10.18632/oncotarget.8531
73
Ozge Saatci, Aysegul Kaymak, Umar Raza, Pelin G. Ersan, Ozge Akbulut, Carolyn E. Banister, Vitali Sikirzhytski, Unal Metin Tokat, Gamze Aykut, Suhail A. Ansari, Hayriye Tatli Dogan, Mehmet Dogan, Pouria Jandaghi, Aynur Isik, Fatma Gundogdu, Kemal Kosemehmetoglu, Omer Dizdar, Sercan Aksoy, Aytekin Akyol, Aysegul Uner, Phillip J. Buckhaults, Yasser Riazalhosseini, Ozgur Sahin. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications 2020; 11(1) doi: 10.1038/s41467-020-16199-4
74
Janis Stiefel, Michael Baßler, Jörn Wittek, Christian Freese. Automated Immunomagnetic Enrichment and Optomicrofluidic Detection to Isolate Breast Cancer Cells: A Proof-of-Concept towards PoC Therapeutic Decision-Making. Magnetochemistry 2022; 8(9) doi: 10.3390/magnetochemistry8090099
75
Mellisa Renteria, Ofek Belkin, David Jang, Justin Aickareth, Muaz Bhalli, Jun Zhang. CmPn signaling networks in the tumorigenesis of breast cancer. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1013892
76
Rhafaela Lima Causin, Mariana Regatieri Polezi, Ana Julia Aguiar de Freitas, Stéphanie Calfa, Wanessa Fernanda Altei, Júlia Oliveira Dias, Ana Carolina Laus, Danielle Pessôa-Pereira, Tatiana Takahasi Komoto, Adriane Feijó Evangelista, Cristiano de Pádua Souza, Rui Manuel Reis, Marcia Maria Chiquitelli Marques. EV-miRNAs from breast cancer patients of plasma as potential prognostic biomarkers of disease recurrence. Heliyon 2024; 10(14) doi: 10.1016/j.heliyon.2024.e33933
77
Tianhong Li, Renfei Wu, Kathy Qian Luo. PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3. Advanced Science 2025; 12(20) doi: 10.1002/advs.202408514
78
Elisa Roda, Fabrizio De Luca, Carmine Di Iorio, Daniela Ratto, Stella Siciliani, Beatrice Ferrari, Filippo Cobelli, Giuseppina Borsci, Erica Cecilia Priori, Silvia Chinosi, Andrea Ronchi, Renato Franco, Raffaele Di Francia, Massimiliano Berretta, Carlo Alessandro Locatelli, Andrej Gregori, Elena Savino, Maria Grazia Bottone, Paola Rossi. Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model. International Journal of Molecular Sciences 2020; 21(10) doi: 10.3390/ijms21103479
79
Natalia Gurvits, Eliisa Löyttyniemi, Marjukka Nykänen, Teijo Kuopio, Pauliina Kronqvist, Kati Talvinen. Separase is a marker for prognosis and mitotic activity in breast cancer. British Journal of Cancer 2017; 117(9) doi: 10.1038/bjc.2017.301
80
Muhseena N. Katheeja, Shankar Prasad Das, Ranajit Das, Suparna Laha. BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple-negative breast cancer severity. Frontiers in Genetics 2023; 14 doi: 10.3389/fgene.2023.1035052
81
Qiuhong Wang, Sheng Gao, Haibo Li, Mingming Lv, Cheng Lu. Long noncoding RNAs (lncRNAs) in triple negative breast cancer. Journal of Cellular Physiology 2017; 232(12) doi: 10.1002/jcp.25830
82
Yaming Li, Ning Zhang, Hanwen Zhang, Qifeng Yang. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma. Journal of Clinical Pathology 2019; 72(6) doi: 10.1136/jclinpath-2018-205544
83
Shuxun Shi, Cong Xu, Xiaonan Fang, Yonghuan Zhang, Hua Li, Wujun Wen, Guiwen Yang. Expression profile of Toll‑like receptors in human breast cancer. Molecular Medicine Reports 2019;  doi: 10.3892/mmr.2019.10853
84
Nazia Chaudhary, Bhagya Shree Choudhary, Anusha Shivashankar, Subhakankha Manna, Khyati Ved, Shagufa Shaikh, Sonal Khanna, Jeetnet Baar, Jagruti Dani, Sarthak Sahoo, R. Soundharya, Mohit Kumar Jolly, Nandini Verma. EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI. Cancer Cell International 2025; 25(1) doi: 10.1186/s12935-025-03691-4
85
G.I. Uscanga-Perales, S.K. Santuario-Facio, R. Ortiz-López. Triple negative breast cancer: Deciphering the biology and heterogeneity. Medicina Universitaria 2016; 18(71) doi: 10.1016/j.rmu.2016.05.007
86
Tamás Mezei, Melinda Hajdu, Gábor Czigléczki, Gábor Lotz, Judit Kocsis, Janina Kulka, Anna Horváth. Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07114-7
87
Bruno Gil, Meysam Keshavarz, Dominic Wales, Ara Darzi, Eric Yeatman. Orthogonal Surface‐Enhanced Raman Scattering/Field‐Effect Transistor Detection of Breast and Colorectal Cancer‐Derived Exosomes using Graphene as a Tag‐Free Diagnostic Template. Advanced NanoBiomed Research 2023; 3(11) doi: 10.1002/anbr.202300055
88
Songrun Han, Feng Wu, Na Yin, Yinghui Wang, Wanying Li, Rui Niu, Yue Cao, Ziqian Wang, Shuyan Song, Hongjie Zhang. Controllable redox therapy hydrogel postoperative implant for triple-negative breast cancer recurrence inhibition. Journal of Rare Earths 2026;  doi: 10.1016/j.jre.2026.08.023
89
Jessica Catarine Frutuoso do Nascimento, Eduardo Isidoro Carneiro Beltrão, Cíntia Renata Costa Rocha. High FUT3 expression is a marker of lower overall survival of breast cancer patients. Glycoconjugate Journal 2020; 37(2) doi: 10.1007/s10719-020-09914-2
90
Chen-Yun Wang, Cing-Hong Wang, Ru-Tsun Mai, Ting-Wen Chen, Chia-Wei Li, Chi-Hong Chao. Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.940402
91
. 2020;  doi: 10.70675/38ea7a7bz655dz40d1z8ef9z6474106f8e19
92
Abhilasha Sinha, Bibbin T. Paul, Lisa M. Sullivan, Hillary Sims, Ahmed El Bastawisy, Hend F. Yousef, Abdel-Rahman N. Zekri, Abeer A. Bahnassy, Wael M. ElShamy. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget 2017; 8(6) doi: 10.18632/oncotarget.14357
93
Andrea Angius, Paolo Cossu-Rocca, Caterina Arru, Maria Rosaria Muroni, Vincenzo Rallo, Ciriaco Carru, Paolo Uva, Giovanna Pira, Sandra Orrù, Maria Rosaria De Miglio. Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype. Cancers 2020; 12(11) doi: 10.3390/cancers12113298
94
Longquan Lou, Ziyi Yu, Yue Wang, Shui Wang, Yi Zhao. c‐Src inhibitor selectively inhibits triple‐negative breast cancer overexpressed Vimentin in vitro and in vivo. Cancer Science 2018; 109(5) doi: 10.1111/cas.13572
95
Eunah Cho, Yeo-Jung Kwon, Dong-Jin Ye, Hyoung-Seok Baek, Tae-Uk Kwon, Hyung-Kyoon Choi, Young-Jin Chun. G0/G1 Switch 2 Induces Cell Survival and Metastasis through Integrin-Mediated Signal Transduction in Human Invasive Breast Cancer Cells. Biomolecules & Therapeutics 2019; 27(6) doi: 10.4062/biomolther.2019.063
96
Insaf Fkih M’hamed, Maud Privat, Mounir Trimeche, Frédérique Penault-Llorca, Yves-Jean Bignon, Abderraouf Kenani. miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers. Pathology & Oncology Research 2017; 23(4) doi: 10.1007/s12253-017-0188-4
97
Gil-Im Mun, Eun Choi, Hee Jin, Seul-Ki Choi, Hanhee Lee, Seoyoung Kim, Junghyun Kim, Chaerin Kang, Hye Lim Oh, Hae-June Lee, Dae-Ro Ahn, Yun-Sil Lee. Phosphorylation of BRCA1 at serine 1387 plays a critical role in cathepsin S-mediated radiation resistance via BRCA1 degradation and BCL2 stabilization. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2025; 1871(1) doi: 10.1016/j.bbadis.2024.167523
98
Su-Hyeong Kim, Eun-Ryeong Hahm, Julie A. Arlotti, Suman K. Samanta, Michelle B. Moura, Stephen H. Thorne, Yongli Shuai, Carolyn J. Anderson, Alexander G. White, Anna Lokshin, Joomin Lee, Shivendra V. Singh. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Research and Treatment 2016; 157(1) doi: 10.1007/s10549-016-3795-y
99
Ella Markalunas, David Arnold, Avery Funkhouser, Julie Martin, Michael Shtutman, W. Edenfield, Anna Blenda. Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients. Genes 2024; 15(6) doi: 10.3390/genes15060818
100
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell Death Discovery 2024; 10(1) doi: 10.1038/s41420-024-02128-7
101
Daniela Massihnia, Alessandro Perez, Viviana Bazan, Giuseppe Bronte, Marta Castiglia, Daniele Fanale, Nadia Barraco, Antonina Cangemi, Florinda Di Piazza, Valentina Calò, Sergio Rizzo, Giuseppe Cicero, Gianni Pantuso, Antonio Russo. A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology 2016; 37(4) doi: 10.1007/s13277-016-4856-x
102
Katheeja Muhseena N, Sooraj Mathukkada, Shankar Prasad Das, Suparna Laha. The repair gene <em>BACH1</em> - a potential oncogene. Oncology Reviews 2021; 15(1) doi: 10.4081/oncol.2021.519
103
Owona Pascal Emmanuel, Mengue Ngadena Yolande Sandrine, Bilanda Danielle Claude, Ayissi Mbomo Rigobert-Espoir, Oluwafemi Adeleke Ojo, Ella Armand Fils, Bidingha A Goufani Ronald, Bindzi Georges Michel, Dzeufiet Djomeni Paul Désiré, Tariq Aziz, Abdulhakeem S. Alamri, Walaa F. Alsanie, Majid Alhomrani. Anti-breast cancer effects of Pterocarpus soyauxii Taub aqueous extract and its compounds by integrating ADMET, network pharmacology, molecular docking, dynamic simulation, CLC-Pred and pdCSM-Cancer/PPI approaches, and in vitro validation. Journal of Ethnopharmacology 2025; 353 doi: 10.1016/j.jep.2025.120407
104
Pei-Jou Chua, Suet-Hui Ow, Cheng-Teng Ng, Wan-Hong Huang, Jie-Ting Low, Puay Hoon Tan, Michael W.Y. Chan, Boon-Huat Bay. Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression. Cancer Cell International 2024; 24(1) doi: 10.1186/s12935-024-03248-x
105
Shubham Upadhyay, Rohan Shetty, T. S. Keshava Prasad. Protein Biomarkers: Discovery and Applications in Clinical Diagnostics. 2024;  doi: 10.1007/978-981-97-5045-0_9
106
Miriam Alvares‑Vilela, Franciele Schlemmer, Sabrina Ferrari, Mary-Ann Xavier, Ricardo Titze‑De‑Almeida. Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review). Oncology Reports 2026; 55(3) doi: 10.3892/or.2026.9047
107
. 2017;  doi: 10.70675/dfcc46cfzb0c1z4de8za16bzda856dc90165
108
I. Roxanis, R. Colling, C. Kartsonaki, A. R. Green, E A. Rakha. The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis. Breast Cancer Research 2018; 20(1) doi: 10.1186/s13058-018-0934-x
109
A-In Kim, Ji Hoon Oh, Je-Yoel Cho. QSOX2 Upregulated in triple-negative breast cancer exacerbates patient prognosis by stabilizing integrin β1. Heliyon 2024; 10(6) doi: 10.1016/j.heliyon.2024.e27148
110
Monica J. Engstrøm, Marit Valla, Anna M. Bofin. Basal markers and prognosis in luminal breast cancer. Breast Cancer Research and Treatment 2017; 163(2) doi: 10.1007/s10549-017-4182-z
111
Siliang Xue, Lang He, Xiao Zhang, Jin Zhou, Fanghua Li, Xiaoshan Wang. Expression of Jagged1/Notch3 Signaling Pathway and their Relationship with the Tumor Angiogenesis in TNBC. Archives of Medical Research 2017; 48(2) doi: 10.1016/j.arcmed.2017.03.014
112
Feng Yang, Michaela Aubele, Axel Walch, Eva Gross, Rudolf Napieralski, Shuo Zhao, Nancy Ahmed, Marion Kiechle, Ute Reuning, Julia Dorn, Fred Sweep, Viktor Magdolen, Manfred Schmitt. Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biological Chemistry 2017; 398(10) doi: 10.1515/hsz-2017-0122
113
Swaroop Kumar Pandey, Mradula Parul, Manikandan Santhanam. Aptamer-guided Selective Delivery of Therapeutics to Breast Cancer Cells Expressing Specific Biomarkers. Current Cancer Therapy Reviews 2024; 20(5) doi: 10.2174/1573394719666230911113126
114
John J. Bassett, Alice H.L. Bong, Ellen K. Janke, Mélanie Robitaille, Sarah J. Roberts-Thomson, Amelia A. Peters, Gregory R. Monteith. Assessment of cytosolic free calcium changes during ceramide-induced cell death in MDA-MB-231 breast cancer cells expressing the calcium sensor GCaMP6m. Cell Calcium 2018; 72 doi: 10.1016/j.ceca.2018.02.003
115
Yonglin Zhao, Xing Wei, Jia Li, Yan Diao, Changyou Shan, Weimiao Li, Shuqun Zhang, Fei Wu. High Level of GMFG Correlated to Poor Clinical Outcome and Promoted Cell Migration and Invasion through EMT Pathway in Triple-Negative Breast Cancer. Genes 2023; 14(6) doi: 10.3390/genes14061157
116
Touko Inao, Yuichi Iida, Tamami Moritani, Tamio Okimoto, Ryosuke Tanino, Hitoshi Kotani, Mamoru Harada. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Oncotarget 2018; 9(39) doi: 10.18632/oncotarget.25370
117
Guochen Zhang, Junlan Wang, Ruilin Zheng, Beibei Song, Li Huang, Yujiang Liu, Yating Hao, Xiangdong Bai. MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells. Technology in Cancer Research & Treatment 2020; 19 doi: 10.1177/1533033820927011
118
Pamungkas Bagus Satriyo, Oluwaseun Adebayo Bamodu, Jia-Hong Chen, Teguh Aryandono, Sofia Mubarika Haryana, Chi-Tai Yeh, Tsu-Yi Chao. Cadherin 11 Inhibition Downregulates β-catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer. Journal of Clinical Medicine 2019; 8(2) doi: 10.3390/jcm8020148
119
Sunil V Jagtap, Shubham S Jagtap. Prognostic significance of stem cell markers: In triple-negative breast cancers. World Journal of Clinical Oncology 2026; 17(7): 119673 doi: 10.5306/wjco.v17.i7.119673
120
Ishita Gupta, Rasha M. Sareyeldin, Israa Al-Hashimi, Hamda A. Al-Thawadi, Halema Al Farsi, Semir Vranic, Ala-Eddin Al Moustafa. Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. Cancers 2019; 11(3) doi: 10.3390/cancers11030363
121
Bin Xiong, Xuefeng Lei, Lei Zhang, Jia Fu. The clinical significance and biological function of olfactomedin 4 in triple negative breast cancer. Biomedicine & Pharmacotherapy 2017; 86 doi: 10.1016/j.biopha.2016.11.081
122
Anindita De, Sonam Patel, K. Gowthamarajan. Functional Smart Nanomaterials and Their Theranostics Approaches. Smart Nanomaterials Technology 2024;  doi: 10.1007/978-981-99-6597-7_5
123
Lucia Motta, Marialuisa Puglisi, Giuliana Pavone, Gianmarco Motta, Federica Martorana, Michelangelo Bambaci, Demetrio Aricò, Paolo Vigneri. Unveiling Prostate-Specific Membrane Antigen’s Potential in Breast Cancer Management. Cancers 2025; 17(3) doi: 10.3390/cancers17030456
124
Peter Hofland. A Potential Biomarker for Treatment Response in Triple-negative Breast Cancer. Onco Zine - The International Oncology Network 2024;  doi: 10.14229/onco.2024.09.13.021
125
Sungyun Kim, Da In Jeong, Mrinmoy Karmakar, Ji‐Won Huh, Eun‐Hye Hong, Dae‐Joon Kim, Hyun‐Jeong Ko, Hyun‐Jong Cho, Ki‐Bum Lee. Multifunctional Bioactive Dual‐Layered Nanofibrous Matrix for Effective Breast Cancer Therapy and Enhanced Wound Healing. Small 2025; 21(31) doi: 10.1002/smll.202500717
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.